Curious to see your top suppliers emissions?
Book a demo for a pilot project
Book a demo for a pilot project
Orexo AB, a prominent player in the pharmaceutical preparation manufacturing industry, is headquartered in Sweden (SE) and operates extensively across Europe and North America. Founded in 1995, Orexo has established itself as a leader in developing innovative treatments for opioid dependence and pain management, with a strong focus on improving patient outcomes.
The company’s core products, including Zubsolv and OX124, are distinguished by their unique formulations and delivery methods, addressing critical needs in addiction treatment and pain relief. Orexo's commitment to research and development has led to significant milestones, positioning it as a trusted name in the pharmaceutical sector. With a robust pipeline and a dedication to advancing healthcare solutions, Orexo continues to make notable strides in the industry, enhancing its market presence and reputation.
0 vs industry average
Orexo’s score of 42 is higher than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
Orexo, a Pharmaceutical Preparation Manufacturing company headquartered in Sweden, reported total emissions of approximately 1,515,000 kg CO2e in 2025. This includes about 312,000 kg CO2e from Scope 2 emissions and approximately 916,000 kg CO2e from Scope 3 emissions. Scope 1 data for 2025 was not provided.
In 2024, Orexo's total emissions were approximately 1,563,000 kg CO2e, comprising about 374,000 kg CO2e from Scope 2 and roughly 877,000 kg CO2e from Scope 3.
For 2023, total emissions were around 1,974,000 kg CO2e, with approximately 379,000 kg CO2e from Scope 2 and 1,322,000 kg CO2e from Scope 3.
In 2022, Orexo's total reported emissions were approximately 2,268,000 kg CO2e. This included about 284,000 kg CO2e from Scope 1, 4,053,000 kg CO2e from Scope 2, and 15,734,000 kg CO2e from Scope 3. It should be noted that there is a discrepancy between the provided total emissions and the sum of the individual scopes for 2022.
Orexo has reported a 3% decrease in combined Scope 1 and Scope 2 emissions in 2023, using 2022 as the base year. This reduction was primarily due to lower emissions from sales travel.
Access structured emission data, company specific factors and auditable source documents
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
No scope 3 category breakdown has been disclosed yet.


You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more